Dizal Pharmaceutical(SH:688192) Xin Lang Zheng Quan·2026-01-21 05:57Core Viewpoint - Dize Pharmaceutical has experienced fluctuations in stock price and trading volume, with a notable increase in revenue but a decrease in net profit for the year 2025 [1][2]. Group 1: Stock Performance - On January 21, Dize Pharmaceutical's stock fell by 2.10%, trading at 61.40 yuan per share, with a total market capitalization of 28.491 billion yuan [1]. - The stock has increased by 6.60% year-to-date, but has decreased by 6.37% over the last five trading days [1]. - The company reported a trading volume of 1.21 billion yuan, with a turnover rate of 0.42% [1]. Group 2: Financial Performance - For the period from January to September 2025, Dize Pharmaceutical achieved a revenue of 586 million yuan, representing a year-on-year growth of 73.23% [2]. - The net profit attributable to shareholders was -580 million yuan, reflecting a year-on-year decrease of 3.85% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 8,806, a rise of 5.01% [2]. - The average number of circulating shares per person increased to 46,528, up by 108.97% compared to the previous period [2]. - Notable changes in institutional holdings include an increase in shares held by Yongying Pharmaceutical Innovation Mixed Fund and the entry of Hong Kong Central Clearing Limited as a new shareholder [2].